REGULATION OF IL-1 GENE-EXPRESSION - DIFFERENTIAL RESPONSIVENESS OF MURINE MACROPHAGE LINES

被引:21
作者
GODAMBE, SA
CHAPLIN, DD
BELLONE, CJ
机构
[1] ST LOUIS UNIV, SCH MED, DEPT MOLEC MICROBIOL & IMMUNOL, ST LOUIS, MO 63104 USA
[2] WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA
[3] WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA
关键词
INTERLEUKIN-1; LIPOPOLYSACCHARIDE; MACROPHAGE;
D O I
10.1016/1043-4666(93)90064-C
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In order to begin to define themechanisms by which lipopolysaccharide (LPS) regulates IL-1 gene expression, we have examined IL-1 RNA levels, the transcription rate of the IL-1 genes, and IL-1 mRNa stabilities in P388DI/C, RAW264.7, and murine peritoneal exudate cells (PEC). These experiments showed that total cellular IL-1 RNa levels and IL-1 transcription rates were dramatically upregulated in all three cell types. In all cases, IL-1α and IL-1β cellular RNA levels and gene transription rates were regulated in parallel. However, the profiles of IL-1 gene activation during the 24 h after LPS treatment differed in these three cell types. Additionally, culture in the presence of actinomycin D (Act D) showed differential stabilities of the IL-1α and IL-1β RNAs in these cells. In peritoneal exudate cells, the half-lives (t1 2) of the IL-1α ad IL-1β RNAs were each >8 h. In RAW 264.7 cells, the stability of the IL-1β RNA was greater than the IL-1α RNA (t1 2 >8 h and ∼6 h, respectively). In P388D1/C cells, the t1 2′s of the IL-1α and β RNAs varied depending on the time of addition of actinomycin D. This and other data suggest that components of the IL-1 RNa catabolic pathway are labile and sensitive to treatment with actinomycin D. Together these data indicate that the two IL-1 genes show a diverse regulatory repertoire, even within related mononuclear phagocytic cells. © 1993 Academie Press Limited.
引用
收藏
页码:327 / 335
页数:9
相关论文
共 32 条
[1]  
AREND WP, 1989, J IMMUNOL, V143, P118
[2]  
CAVAILLON J-M, 1990, Cytokine, V2, P313, DOI 10.1016/1043-4666(90)90061-W
[3]   ISOLATION OF BIOLOGICALLY-ACTIVE RIBONUCLEIC-ACID FROM SOURCES ENRICHED IN RIBONUCLEASE [J].
CHIRGWIN, JM ;
PRZYBYLA, AE ;
MACDONALD, RJ ;
RUTTER, WJ .
BIOCHEMISTRY, 1979, 18 (24) :5294-5299
[4]   GENOMIC SEQUENCE FOR HUMAN PROINTERLEUKIN-1-BETA - POSSIBLE EVOLUTION FROM A REVERSE TRANSCRIBED PROINTERLEUKIN-1-ALPHA GENE [J].
CLARK, BD ;
COLLINS, KL ;
GANDY, MS ;
WEBB, AC ;
AURON, PE .
NUCLEIC ACIDS RESEARCH, 1986, 14 (20) :7897-7914
[5]  
COLLART MA, 1987, J IMMUNOL, V139, P949
[6]  
DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13
[7]  
DINARELLO CA, 1989, B NEW YORK ACAD MED, V65, P80
[8]   INTERLEUKIN-1 [J].
DINARELLO, CA .
REVIEWS OF INFECTIOUS DISEASES, 1984, 6 (01) :51-95
[9]  
DONNELLY RP, 1990, J IMMUNOL, V145, P569
[10]  
DURUM SK, 1985, ANNU REV IMMUNOL, V3, P263